Following today’s Court of Appeal ruling on the commissioning of Pre-Exposure Prophylaxis (PrEP) by NHS England (NHSE), the Association of the British Pharmaceutical Industry (ABPI) has responded calling for NHSE to commit to constructive dialogue that's considerate of breakthrough medical advances in order to deliver a commissioning process that is transparent, consistent and fair.
Dr Richard Torbett, Executive Director – Commercial, ABPI said:
"We are pleased that this case has come to a close, and NHS England should now deliver a speedy resolution to its 2015/16 decision making process to ensure that patients who have been left in limbo can finally have access to a number of life-changing medicines and treatments, without further delay.
This case shows that NHS England's existing system for specialised commissioning is opaque and unpredictable. Instead of attempting to negotiate pricing through press releases, we believe that NHS England should comprehensively assess the value of a medicine to patients, through a clearly laid out commissioning and decision-making process. This will give patients and industry confidence that NHS England is making fair and appropriate decisions.
Within this debate, we remain acutely aware of the state of current NHS finances, yet it shouldn't be forgotten that our members already play their part in meeting budget constraints. Under the 2014-2018 Pharmaceutical Price Regulation Scheme (PPRS), set up to address the NHS affordability issue for new medicines, the pharmaceutical industry has already paid more than £1billion back to the Department of Health.
There remains a legitimate debate to be had on current levels of healthcare spending and a sensible balance needs to be struck to reverse the slow and low uptake of medical innovation here in the UK."
## ENDS ##
ABPI Press OfficeEmail: email@example.comTelephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.